<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04552041</url>
  </required_header>
  <id_info>
    <org_study_id>MMH-MAP-003</org_study_id>
    <nct_id>NCT04552041</nct_id>
  </id_info>
  <brief_title>Prospecta in the Treatment of Cognitive, Behavioural and Psychiatric Disorders in Patients With Vascular Dementia.</brief_title>
  <official_title>Multicenter Double-blind Placebo-controlled Parallel-group Randomized Clinical Trial of Efficacy and Safety of Prospecta in the Treatment of Cognitive, Behavioural and Psychiatric Disorders in Patients With Vascular Dementia.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Materia Medica Holding</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Materia Medica Holding</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study purpose:&#xD;
&#xD;
      - evaluate safety and clinical efficacy of Prospecta in the treatment of cognitive,&#xD;
      behavioural and psychiatric disorders in patients with vascular dementia.&#xD;
&#xD;
      Study objectives:&#xD;
&#xD;
        -  evaluate and compare changes in cognitive functions and in behavioural and psychiatric&#xD;
           dementia symptoms in Prospecta and Placebo groups after 24-week therapy:&#xD;
&#xD;
        -  evaluate and compare the frequency, severity and causal relationship of adverse events&#xD;
           (AEs) with the type of therapy in Prospecta and Placebo groups (including central&#xD;
           nervous system AEs during therapy, their relationship with the product and other&#xD;
           characteristics).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Design: a multicenter double blind placebo-controlled parallel-group randomized clinical&#xD;
      trial. The study will enroll male and female subjects aged 60-85 years diagnosed with&#xD;
      vascular dementia (verified at Visit 1 and diagnosed according to the criteria of The&#xD;
      National Institute of Neurological Disorders and Stroke National Institute of Neurological&#xD;
      Disorders and Stroke-Association Internationale pour la Recherche et l'Enseignement en&#xD;
      Neurosciences - NINDS-AIREN). Severity of vascular dementia should be moderate or mild (10-24&#xD;
      points according to Mini-Mental State Examination - MMSE), without signs of depression (total&#xD;
      Cornell Scale for Depression in Dementia (CSDD) score ≤10).&#xD;
&#xD;
      After signing patient information sheet (informed consent form), investigator will collect&#xD;
      complaints and medical history, perform objective examination, record vital signs (blood&#xD;
      pressure (BP), respiratory rate (RR), heart rate (HR)) and evaluate the compliance of the&#xD;
      subject's diagnosis with NINDS-AIREN vascular criteria of dementia (Visit 1; from day -14 to&#xD;
      day 1). The investigator will assess cognitive disorders using Mini-Mental State Examination&#xD;
      (MMSE) and Montreal Сognitive Assessment (МоСА). The investigator will fill the&#xD;
      Neuropsychiatric Inventory Сlinician (NPI-С), and СSDD scales. The subject will undergo brain&#xD;
      MRI (unless brain MRI was held within the last 12 months prior to enrollment are available).&#xD;
&#xD;
      Concomitant therapy and concurrent diseases and conditions will be recorded. If subject met&#xD;
      inclusion criteria, he/she will be randomized to one of the two groups: group 1 will receive&#xD;
      Prospecta 2 tablets twice daily; group 2 will receive Placebo using the study drug dosing&#xD;
      regimen.&#xD;
&#xD;
      Treatment duration will be 24 weeks during which 6 Visits will be made. At visits 2 and 3&#xD;
      (week 4±3 days and week 8±3 days) the investigator will make a phone call and collect the&#xD;
      complaints, monitor the prescribed and concomitant therapy, evaluate therapeutic safety.&#xD;
&#xD;
      At visit 4 (week 12±7 days) the investigator will collect complaints, record objective&#xD;
      examination findings and vital signs, monitor the prescribed and concomitant therapy,&#xD;
      evaluate therapeutic safety and compliance, issue the study product until the next visit. The&#xD;
      investigator will fill MoCA and NPI-C.&#xD;
&#xD;
      At visits 5 and 6 (week 16±3 days and week 20±3 days) the investigator will make a phone call&#xD;
      and collect the complaints, monitor the prescribed and concomitant therapy, evaluate&#xD;
      therapeutic safety.&#xD;
&#xD;
      At visit 7 (week 24±7 days) the investigator will collect complaints, perform objective&#xD;
      examination, record vital signs, monitor the prescribed and concomitant therapy, evaluate&#xD;
      therapeutic safety, evaluate compliance. The investigator will fill MоСА and Clinical Global&#xD;
      Impression Efficacy Index (CGI-EI). The investigator will fill NPI-C.&#xD;
&#xD;
      During the study the treatment for underlying medical conditions will be allowed with the&#xD;
      exception of the drugs indicated in the section &quot;Prohibited concomitant therapy&quot;.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 3, 2020</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>double-blind placebo-controlled randomized</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in mean Montreal Сognitive Assessment (MoCA) score</measure>
    <time_frame>24 weeks</time_frame>
    <description>Montreal Сognitive Assessment is used to evaluate changes in cognitive function. It assesses multiple cognitive domains: attention, concentration, executive functions, memory, language, visuospatial skills, abstraction, calculation and orientation. Maximum score is 30; score ≥ 26 is considered to be normal.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in mean NPI-С score</measure>
    <time_frame>24 weeks</time_frame>
    <description>Neuropsychiatric Inventory-Clinician (NPI-C) allows to evaluate severity of behavioural and mental disorders associated with dementia. The scale consists of 14 domains evaluating frequency and severity of delusional ideas, hallucinations, agitation, aggression, dysphoria, anxiety, euphoria, apathy, disinhibition, irritability, aberrant motor behaviour, sleep and appetite disorders, aberrant vocalizations. Scoring for &quot;delusional ideas&quot; (8 items) is 0-24 points, for &quot;hallucinations&quot; (7 items) - 0-21, &quot;agitation&quot; (13 items) - 0-39, &quot;aggression&quot; (8 items) - 0-24, &quot;dysphoria&quot; (13 items) - 0-39, &quot;anxiety&quot; (14 items) - 0-42, &quot;euphoria&quot; (6 items) - 0-18, &quot;apathy&quot; (11 items) - 0-33, &quot;disinhibition&quot; (16 items) - 0-48, &quot;irritability&quot; (12 items) - 0-36 , &quot;aberrant motor behaviour&quot; (9 items) - 0-27, &quot;sleep disorders&quot; (8 items) - 0-24, &quot;appetite disorders&quot; (9 items) - 0-27, &quot;aberrant vocalizations&quot; (8 items) - 0-24.&#xD;
Total maximum score for all domains is 426.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in mean Montreal Сognitive Assessment (MoCA) score</measure>
    <time_frame>12 weeks</time_frame>
    <description>Montreal Сognitive Assessment is used to evaluate changes in cognitive function. It assesses multiple cognitive domains: attention, concentration, executive functions, memory, language, visuospatial skills, abstraction, calculation and orientation. Maximum score is 30; score ≥ 26 is considered to be normal.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in mean Neuropsychiatric Inventory-Clinician (NPI-С) score</measure>
    <time_frame>12 weeks</time_frame>
    <description>Neuropsychiatric Inventory-Clinician (NPI-C) allows to evaluate severity of behavioural and mental disorders associated with dementia. The scale consists of 14 domains evaluating frequency and severity of delusional ideas, hallucinations, agitation, aggression, dysphoria, anxiety, euphoria, apathy, disinhibition, irritability, aberrant motor behaviour, sleep and appetite disorders, aberrant vocalizations. Scoring for &quot;delusional ideas&quot; (8 items) is 0-24 points, for &quot;hallucinations&quot; (7 items) - 0-21, &quot;agitation&quot; (13 items) - 0-39, &quot;aggression&quot; (8 items) - 0-24, &quot;dysphoria&quot; (13 items) - 0-39, &quot;anxiety&quot; (14 items) - 0-42, &quot;euphoria&quot; (6 items) - 0-18, &quot;apathy&quot; (11 items) - 0-33, &quot;disinhibition&quot; (16 items) - 0-48, &quot;irritability&quot; (12 items) - 0-36 , &quot;aberrant motor behaviour&quot; (9 items) - 0-27, &quot;sleep disorders&quot; (8 items) - 0-24, &quot;appetite disorders&quot; (9 items) - 0-27, &quot;aberrant vocalizations&quot; (8 items) - 0-24.&#xD;
Total maximum score for all domains is 426.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Clinical Global Impression Efficacy Index (СGI-EI) score</measure>
    <time_frame>24 weeks</time_frame>
    <description>Clinical Global Impression Efficacy Index (CGI-EI). TheCGI-E is a 4×4 rating scale that assesses the therapeutic effect of treatment with psychiatric medication and associated side effects.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">406</enrollment>
  <condition>Vascular Dementia</condition>
  <arm_group>
    <arm_group_label>Prospecta</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two tablets per intake 2 times a day (approximately at the same time), outside of meal (between meals or 15 minutes prior to meal or drinking). The tablets should be held in mouth until completely dissolved.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Two tablets per intake 2 times a day (approximately at the same time), outside of meal (between meals or 15 minutes prior to meal or drinking). The tablets should be held in mouth until completely dissolved.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prospecta</intervention_name>
    <description>Oral administration.</description>
    <arm_group_label>Prospecta</arm_group_label>
    <other_name>MMH-MAP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral administration.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subjects aged 60-85 years old.&#xD;
&#xD;
          2. Subjects with verified diagnosis of vascular dementia.&#xD;
&#xD;
          3. Presence of all the vascular dementia criteria according to National Institute of&#xD;
             Neurological Disorders and Stroke and Association Internationale pour la Recherche et&#xD;
             l'Enshrinement en Neurosciences (NINDS-AIREN) criteria:&#xD;
&#xD;
               1. Cognitive disorder syndrome:&#xD;
&#xD;
                    -  dysregulatory disorders: impaired aim formation, abstraction, initiation,&#xD;
                       planning, organization and maintenance of activities;&#xD;
&#xD;
                    -  memory disorders (may be moderate) consisting in impaired reproduction&#xD;
                       against relatively retained recognition and efficacy of cues.&#xD;
&#xD;
               2. Presence of a cerebrovascular disease:&#xD;
&#xD;
                    -  according to brain imaging (expressed hypotensive irregular, &quot;spotty&quot;, foci&#xD;
                       located periventricularly and in deep segments of white matter or diffuse&#xD;
                       symmetrical low-density changes in semioval center projection combined with&#xD;
                       at least one lacunar focus; lack of nonlacunar cortical or&#xD;
                       cortical-subcortical infarctions and signs of cerebral damage of another&#xD;
                       etiology);&#xD;
&#xD;
                    -  focal symptoms in neurological status or their evidence in the history&#xD;
                       (hemiparesis, weakness of the lower part of facial muscles, Babinski's&#xD;
                       symptom, sensitivity disorders, dysarthria, gait disorders, extrapyramidal&#xD;
                       symptoms which may be explained by subcortical foci).&#xD;
&#xD;
               3. Temporal relationship between dementia and cerebrovascular disorders (except for&#xD;
                  cases of subcortical vascular dementia): onset of dementia within 3-6 months&#xD;
                  post-stroke, sudden exacerbation of cognitive functions, step-wise progression of&#xD;
                  cognitive disorders.&#xD;
&#xD;
          4. Availability of permanent caregiver throughout the study (nurse or relatives).&#xD;
&#xD;
          5. Total Mini-Mental State Examination (MMSE) score - 10-24.&#xD;
&#xD;
          6. Total MoCA score &lt;26.&#xD;
&#xD;
          7. Total NPI-C aggression and agitation domain score ≥14.&#xD;
&#xD;
          8. Аbsence of depression (total Cornell Scale for Depression in Dementia (CSDD) score&#xD;
             ≤10).&#xD;
&#xD;
          9. Brain Magnetic Resonance Imaging (MRI) confirming the diagnosis of vascular dementia&#xD;
             within 1 year prior to enrollment (or brain MRI performed at enrollment visit).&#xD;
&#xD;
         10. Subjects giving their consent to use reliable contraception throughout the study (for&#xD;
             males).&#xD;
&#xD;
         11. Availability of signed patient information sheet and informed consent form for&#xD;
             participation in the clinical trial.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Signs of intracerebral hemorrhage, brain tumours causing dementia.&#xD;
&#xD;
          2. Alzheimer's disease, Parkinson disease, Lewy body dementia, multiple system atrophy,&#xD;
             Jacob-Creutzfeld disease, Pick syndrome, corticobasal degeneration.&#xD;
&#xD;
          3. Injuries of head (S00-S09 International Statistical Classification of Diseases and&#xD;
             Related Health Problems (ICD)-10) associated with impaired consciousness, cerebral&#xD;
             contusion or open craniocerebral traumas.&#xD;
&#xD;
          4. Toxicity-related dementia (including drug-induced), multiorgan failure or metabolic&#xD;
             and toxic disorders (chronic hypothyroidism, decompensated diabetes mellitus,&#xD;
             avitaminoses, etc.).&#xD;
&#xD;
          5. Other psychiatric diseases besides dementia: mental disorders and behavioral disorders&#xD;
             due to use of psychoactive substances (F10-19 ICD-10), schizophrenia, schizotypal and&#xD;
             delusional disorders (F20-29 ICD-10).&#xD;
&#xD;
          6. Mental retardation(F70-79 ICD-10).&#xD;
&#xD;
          7. Inflammatory lesions of the brain with persistent neurological deficit.&#xD;
&#xD;
          8. Malignant neoplasms.&#xD;
&#xD;
          9. Previously diagnosed cardiovascular diseases with functional class III or IV&#xD;
             (according to New York Heart Association, 1964).&#xD;
&#xD;
         10. Unstable angina pectoris, myocardial infarction or ischemic stroke within the last 6&#xD;
             months.&#xD;
&#xD;
         11. Female with childbearing potential.&#xD;
&#xD;
         12. Allergy/intolerance of any of the study product components including secondary to&#xD;
             lactase deficiency.&#xD;
&#xD;
         13. Any conditions which will prevent from the subject's participation in the study,&#xD;
             according to investigator's opinion.&#xD;
&#xD;
         14. History of treatment noncompliance, mental diseases, alcoholism or drug abuse which&#xD;
             will prevent from following the study procedures, according to investigator's opinion.&#xD;
&#xD;
         15. Participation in clinical trials for 3 months prior to enrollment in this study.&#xD;
&#xD;
         16. The patient is the study site employee directly involved in the study, or is an&#xD;
             immediate family member of the investigator or has another conflict of interests.&#xD;
             Spouses, parents, children, or siblings, regardless of whether they are siblings or&#xD;
             adopted are considered immediate family members.&#xD;
&#xD;
         17. The patient works at &quot;Materia Medica Holding&quot;, i.e. they are employees of the Company,&#xD;
             temporary employees on a contract basis or appointed officials responsible for&#xD;
             conduction of the study or their immediate family members.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pavel Kamchatnov, professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>V.M. Buyanov Moscow City Clinical Hospital, Moscow, Russia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mikhail Putilovskiy, MD, PhD</last_name>
    <phone>+74952761575</phone>
    <phone_ext>302</phone_ext>
    <email>PutilovskiyMA@materiamedica.ru</email>
  </overall_contact>
  <location>
    <facility>
      <name>Northern State Medical University/Department of Family Medicine and Internal Medicine</name>
      <address>
        <city>Arkhangelsk</city>
        <zip>163000</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nina Khasanova, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Nina Khasanova, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Belgorod Regional Clinical Hospital of St. Joasaph/Neurological department</name>
      <address>
        <city>Belgorod</city>
        <zip>308007</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Janna Chefranova, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Janna Chefranova, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital &quot;Russian Railways - Medicine&quot; of the city of Bryansk/Medical rehabilitation department</name>
      <address>
        <city>Bryansk</city>
        <zip>241004</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marina Agafonova, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Marina Agafonova, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sverdlovsk Regional Clinical Psychiatric Hospital</name>
      <address>
        <city>Ekaterinburg</city>
        <zip>6620030</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Malakhova, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Anna Malakhova, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Engels Psychiatric Hospital</name>
      <address>
        <city>Engels</city>
        <zip>413124</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dmitry Ivliev, MD</last_name>
    </contact>
    <investigator>
      <last_name>Dmitry Ivliev, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kazan State Medical University/Department of Neurology and Rehabilitation</name>
      <address>
        <city>Kazan</city>
        <zip>420012</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Enver Bogdanov, Prof.</last_name>
    </contact>
    <investigator>
      <last_name>Enver Bogdanov, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Research Institute - Regional Clinical Hospital #1 named after prof. S.V. Ochapovsky</name>
      <address>
        <city>Krasnodar</city>
        <zip>350086</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lyudmila Timchenko, MD</last_name>
    </contact>
    <investigator>
      <last_name>Lyudmila Timchenko, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>City Clinical Hospital named after V.M. Buyanov of the Moscow City Health Department/1st neurological department</name>
      <address>
        <city>Moscow</city>
        <zip>115516</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pavel Kamchatnov, Prof.</last_name>
    </contact>
    <investigator>
      <last_name>Pavel Kamchatnov, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Peoples' Friendship University of Russia/Department of Psychiatry, Psychotherapy and Psychosomatic Pathology</name>
      <address>
        <city>Moscow</city>
        <zip>117198</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vladimir Medvedev, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Vladimir Medvedev, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Central Clinical Hospital of the Russian Academy of Sciences/Treatment and Diagnostic Center</name>
      <address>
        <city>Moscow</city>
        <zip>117593</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Oleg Tyurin, MD</last_name>
    </contact>
    <investigator>
      <last_name>Oleg Tyurin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Psychiatric hospital # 1 named after P.P. Kashchenko</name>
      <address>
        <city>Nikol'skoye</city>
        <zip>188357</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alexey Raspopov, MD</last_name>
    </contact>
    <investigator>
      <last_name>Alexey Raspopov, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Privolzhsky Research Medical University/Department of Medical Rehabilitation</name>
      <address>
        <city>Nizhny Novgorod</city>
        <zip>603005</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Belova, Prof.</last_name>
    </contact>
    <investigator>
      <last_name>Anna Belova, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nizhny Novgorod Regional Clinical Hospital. N. A. Semashko/Outpatient department</name>
      <address>
        <city>Nizhny Novgorod</city>
        <zip>603126</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Elena Antipenko, Prof.</last_name>
    </contact>
    <investigator>
      <last_name>Elena Antipenko, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Llc &quot;Medis&quot;</name>
      <address>
        <city>Nizhny Novgorod</city>
        <zip>603137</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Irina Sokolova, MD</last_name>
    </contact>
    <investigator>
      <last_name>Irina Sokolova, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Orenburg Regional Clinical Psychiatric Hospital # 1/Psychoneurological dispensary</name>
      <address>
        <city>Orenburg</city>
        <zip>460006</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elena Kryukova, MD</last_name>
    </contact>
    <investigator>
      <last_name>Elena Kryukova, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pyatigorsk City Clinical Hospital # 2/Neurological department</name>
      <address>
        <city>Pyatigorsk</city>
        <zip>357538</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gennadiy Mishin, MD</last_name>
    </contact>
    <investigator>
      <last_name>Gennadiy Mishin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>LLC &quot;Treatment and reabilitation research center &quot; PHOENIX &quot;/Day hospital # 1</name>
      <address>
        <city>Rostov-on-Don</city>
        <zip>344000</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olga Bukhanovskaya, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Olga Bukhanovskaya, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Psychoneurological dispensary # 10/Medical rehabilitation department</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>190121</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ekaterina Smetannikova, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Ekaterina Smetannikova, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Nicholas Psychiatric Hospital</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>190121</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Vladimir Tochilov, Prof.</last_name>
    </contact>
    <investigator>
      <last_name>Vladimir Tochilov, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Petersburg Research Institute of Emergency Medicine named after I.I. Janelidze/Medical Rehabilitation Department</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>192242</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Igor Voznyuk, Prof.</last_name>
    </contact>
    <investigator>
      <last_name>Igor Voznyuk, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Psychoneurological dispensary # 5/Day hospital</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>195176</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lyubov Gluskina, MD</last_name>
    </contact>
    <investigator>
      <last_name>Lyubov Gluskina, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>LLC &quot;National Center for Socially Significant Diseases&quot;</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>197110</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Maria Shumilina, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Maria Shumilina, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Leningrad Regional Clinical Hospital/Neurological department</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>194291</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Leonid Zaslavskiy, Prof.</last_name>
    </contact>
    <investigator>
      <last_name>Leonid Zaslavskiy, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Samara City Clinical Hospital # 1 named after N.I. Pirogov/Neurological department for patients with cerebrovascular accident # 24</name>
      <address>
        <city>Samara</city>
        <zip>443096</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tatiana Lokshtanova, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Tatiana Lokshtanova, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saratov State Medical University V. I. Razumovsky/Department of Neurology named after K.N. Tretyakov</name>
      <address>
        <city>Saratov</city>
        <zip>410012</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Oleg Kolokolov, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Oleg Kolokolov, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>City Clinical Hospital # 2 named after V.I. Razumovsky</name>
      <address>
        <city>Saratov</city>
        <zip>410028</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Julia Barylnik, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Julia Barylnik, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saratov City Psychoneurological Dispensary</name>
      <address>
        <city>Saratov</city>
        <zip>410038</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alexey Kokoshnikov, MD</last_name>
    </contact>
    <investigator>
      <last_name>Alexey Kokoshnikov, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Regional Clinical Psychiatric Hospital of St. Sophia</name>
      <address>
        <city>Saratov</city>
        <zip>410060</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alexander Parashchenko, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Alexander Parashchenko, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Smolensk Regional Clinical Hospital</name>
      <address>
        <city>Smolensk</city>
        <zip>214018</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Strachunskaya, MD</last_name>
    </contact>
    <investigator>
      <last_name>Maria Strachunskaya, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stavropol Regional Clinical Specialized Psychiatric Hospital # 1/Somatogeriatric department #19</name>
      <address>
        <city>Stavropol</city>
        <zip>355038</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Oleg Boyev, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Oleg Boyev, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Republican Clinical Hospital named after G.G. Kuvatov</name>
      <address>
        <city>Ufa</city>
        <zip>450005</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Klara Bakhtiyarova, Prof.</last_name>
    </contact>
    <investigator>
      <last_name>Klara Bakhtiyarova, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bashkir State Medical University/Department of Neurology</name>
      <address>
        <city>Ufa</city>
        <zip>450008</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Leyla Akhmadeyeva, Prof.</last_name>
    </contact>
    <investigator>
      <last_name>Leyla Akhmadeyeva, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ulyanovsk Regional Clinical Hospital/Outpatient department</name>
      <address>
        <city>Ulyanovsk</city>
        <zip>432063</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Irina Greshnova, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Irina Greshnova, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Regional Clinic Hospital</name>
      <address>
        <city>Vladimir</city>
        <zip>600023</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Julia Gerasimova, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Julia Gerasimova, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Volgograd State Medical University/Department of Neurology, Neurosurgery with the Course of Medical Genetics</name>
      <address>
        <city>Volgograd</city>
        <zip>400131</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Olga Kurushina, Md, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Olga Kurushina, Md, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vsevolozhsk clinical interdistrict hospital/Neurological department</name>
      <address>
        <city>Vsevolozhsk</city>
        <zip>188643</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Liya Lukinykh, MD</last_name>
    </contact>
    <investigator>
      <last_name>Liya Lukinykh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yaroslavl Regional Psychiatric Hospital</name>
      <address>
        <city>Yaroslavl</city>
        <state>Москва</state>
        <zip>150003</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Irina Zayarnaya, MD</last_name>
    </contact>
    <investigator>
      <last_name>Irina Zayarnaya, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 10, 2020</study_first_submitted>
  <study_first_submitted_qc>September 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 17, 2020</study_first_posted>
  <last_update_submitted>March 17, 2021</last_update_submitted>
  <last_update_submitted_qc>March 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dementia</mesh_term>
    <mesh_term>Dementia, Vascular</mesh_term>
    <mesh_term>Mental Disorders</mesh_term>
    <mesh_term>Problem Behavior</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

